These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 37632520)

  • 1. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization.
    Manas D; Bell JK; Mealing S; Davies H; Baker H; Holmes H; Hubner RA
    Eur J Surg Oncol; 2021 Feb; 47(2):401-408. PubMed ID: 32958370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant.
    Wu X; Kwong A; Heller M; Lokken RP; Fidelman N; Mehta N
    Liver Transpl; 2024 Feb; 30(2):151-159. PubMed ID: 37639286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
    Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
    Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study comparing the cost-effectiveness of conventional and drug-eluting transarterial chemoembolisation (cTACE and DEB-TACE) for the treatment of hepatocellular carcinoma in an Australian public hospital.
    Clements W; Chenoweth A; Phipps B; Mozo L; Bolger M; Morphett L; Phan T; Koukounaras J; Lukies MW
    J Med Imaging Radiat Oncol; 2024 Sep; 68(6):714-720. PubMed ID: 38985987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial radioembolization vs transarterial chemoembolization with drug-eluting beads for treating hepatocellular carcinoma: a cost-effectiveness analysis in Japanese healthcare system.
    Shirota G; Sato S; Yasunaga H; Aso S; Akahane M; Itoh D; Abe O
    Jpn J Radiol; 2024 Dec; 42(12):1501-1515. PubMed ID: 39325293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Wu X; Chapiro J; Malhotra A; Kothary N
    J Vasc Interv Radiol; 2021 Jan; 32(1):2-12.e1. PubMed ID: 33160827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
    Yang B; Liang J; Qu Z; Yang F; Liao Z; Gou H
    PLoS One; 2020; 15(2):e0227475. PubMed ID: 32074102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma.
    Cucchetti A; Trevisani F; Cappelli A; Mosconi C; Renzulli M; Pinna AD; Golfieri R
    Dig Liver Dis; 2016 Jul; 48(7):798-805. PubMed ID: 27263056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
    Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
    Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective.
    Narayanan A; Garza-Berlanga A; Lopera J
    Ann Palliat Med; 2023 Nov; 12(6):1244-1259. PubMed ID: 37574584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
    PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review.
    Alonso JC; Casans I; González FM; Fuster D; Rodríguez A; Sánchez N; Oyagüez I; Burgos R; Williams AO; Espinoza N
    BMC Gastroenterol; 2022 Jul; 22(1):326. PubMed ID: 35780112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
    Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
    Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR
    Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.